BR112017023199A2 - “peptídeo com atividade antiobesidade, antidiabetes e uso do mesmo” - Google Patents
“peptídeo com atividade antiobesidade, antidiabetes e uso do mesmo”Info
- Publication number
- BR112017023199A2 BR112017023199A2 BR112017023199A BR112017023199A BR112017023199A2 BR 112017023199 A2 BR112017023199 A2 BR 112017023199A2 BR 112017023199 A BR112017023199 A BR 112017023199A BR 112017023199 A BR112017023199 A BR 112017023199A BR 112017023199 A2 BR112017023199 A2 BR 112017023199A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- present
- obesity
- drugs
- expression
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 230000000694 effects Effects 0.000 title abstract 4
- 230000003579 anti-obesity Effects 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 101100214824 Caenorhabditis elegans abhd-5.2 gene Proteins 0.000 abstract 1
- 101150024973 PNPLA2 gene Proteins 0.000 abstract 1
- 101150014691 PPARA gene Proteins 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 210000001789 adipocyte Anatomy 0.000 abstract 1
- 230000002293 adipogenic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002366 lipolytic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
um peptídeo e um complexo peptídico da presente invenção exibem um efeito anti-obesidade, inibindo o acúmulo de gordura e a decompondo a gordura já acumulada, e exibem um excelente efeito em relação ao diabetes reduzindo efetivamente o açúcar no sangue. o peptídeo e o complexo peptídico da presente invenção diminuem a expressão de ppar¿, acc e ap2, que são marcadores adipogênicos, aumentam a expressão de phsl, ampk-a1, cgi-58 e atgl, que são fatores lipolíticos e reduzem o tamanho das células de gordura e os valores de colesterol no sangue. o peptídeo e o complexo peptídico da presente invenção, que têm excelente atividade e segurança, podem ser vantajosamente aplicados a fármacos e quase-fármacos.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR122020019171-6A BR122020019171B1 (pt) | 2015-04-28 | 2015-05-12 | Peptídeo com atividade antiobesidade, antidiabetes e uso do mesmo |
| BR122020019077-9A BR122020019077B1 (pt) | 2015-04-28 | 2015-05-12 | Peptídeo com atividade antiobesidade, antidiabetes e uso do mesmo |
| BR122020019095-7A BR122020019095B1 (pt) | 2015-04-28 | 2015-05-12 | Peptídeo com atividade antiobesidade, antidiabetes e uso do mesmo |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150059648A KR101669140B1 (ko) | 2015-04-28 | 2015-04-28 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
| KR10-2015-0059648 | 2015-04-28 | ||
| PCT/KR2015/004749 WO2016175362A1 (ko) | 2015-04-28 | 2015-05-12 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017023199A2 true BR112017023199A2 (pt) | 2019-01-29 |
| BR112017023199B1 BR112017023199B1 (pt) | 2023-11-07 |
Family
ID=57198486
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122020019077-9A BR122020019077B1 (pt) | 2015-04-28 | 2015-05-12 | Peptídeo com atividade antiobesidade, antidiabetes e uso do mesmo |
| BR122020019171-6A BR122020019171B1 (pt) | 2015-04-28 | 2015-05-12 | Peptídeo com atividade antiobesidade, antidiabetes e uso do mesmo |
| BR112017023199-9A BR112017023199B1 (pt) | 2015-04-28 | 2015-05-12 | Peptídeo com atividade antiobesidade, antidiabetes e uso do mesmo |
| BR122020019095-7A BR122020019095B1 (pt) | 2015-04-28 | 2015-05-12 | Peptídeo com atividade antiobesidade, antidiabetes e uso do mesmo |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122020019077-9A BR122020019077B1 (pt) | 2015-04-28 | 2015-05-12 | Peptídeo com atividade antiobesidade, antidiabetes e uso do mesmo |
| BR122020019171-6A BR122020019171B1 (pt) | 2015-04-28 | 2015-05-12 | Peptídeo com atividade antiobesidade, antidiabetes e uso do mesmo |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122020019095-7A BR122020019095B1 (pt) | 2015-04-28 | 2015-05-12 | Peptídeo com atividade antiobesidade, antidiabetes e uso do mesmo |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US10351597B2 (pt) |
| EP (4) | EP3613759B1 (pt) |
| JP (4) | JP6606192B2 (pt) |
| KR (1) | KR101669140B1 (pt) |
| CN (3) | CN110105432B (pt) |
| AU (4) | AU2015393357B2 (pt) |
| BR (4) | BR122020019077B1 (pt) |
| CA (4) | CA3074800C (pt) |
| CL (4) | CL2017002718A1 (pt) |
| CO (1) | CO2017011998A2 (pt) |
| EA (1) | EA037799B1 (pt) |
| ES (4) | ES2893468T3 (pt) |
| HK (1) | HK1252251A1 (pt) |
| IL (4) | IL255263B (pt) |
| MX (4) | MX2017013847A (pt) |
| MY (4) | MY197888A (pt) |
| NZ (4) | NZ747392A (pt) |
| PH (1) | PH12017501983A1 (pt) |
| SA (4) | SA517390237B1 (pt) |
| SG (4) | SG10201913490WA (pt) |
| WO (1) | WO2016175362A1 (pt) |
| ZA (1) | ZA201708044B (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101669140B1 (ko) | 2015-04-28 | 2016-10-26 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
| KR101831888B1 (ko) * | 2016-04-15 | 2018-04-16 | (주)케어젠 | 항염증 활성을 갖는 펩타이드 및 이의 용도 |
| KR101887576B1 (ko) | 2016-04-15 | 2018-08-13 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
| KR101955511B1 (ko) * | 2016-08-17 | 2019-03-11 | (주)진셀팜 | 지방분해 촉진 효과를 가지는 펩타이드, 및 이의 용도 |
| KR101887577B1 (ko) * | 2016-10-19 | 2018-09-10 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
| KR102386705B1 (ko) * | 2016-11-07 | 2022-04-21 | 주식회사 삼양사 | 알룰로스의 항비만 활성 관련 마커 유전자 및 이의 용도 |
| CN106749533B (zh) * | 2016-12-05 | 2020-08-18 | 华南理工大学 | 一种抗肥胖十七肽lnnpsvcdcdcmmkaar |
| CN106518971B (zh) * | 2016-12-05 | 2019-12-10 | 华南理工大学 | 一种抗肥胖十肽canphelpnk |
| CN106749524B (zh) * | 2016-12-05 | 2020-08-18 | 华南理工大学 | 一种抗肥胖七肽npvwkrk |
| CN106699846B (zh) * | 2016-12-05 | 2020-08-18 | 华南理工大学 | 一种抗肥胖十一肽nalkcchscpa |
| JP2019034926A (ja) * | 2017-08-10 | 2019-03-07 | 小林製薬株式会社 | 加齢性肥満改善剤及び脂肪分解力改善剤 |
| KR101920047B1 (ko) | 2018-01-03 | 2018-11-19 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
| KR102065150B1 (ko) | 2018-04-27 | 2020-01-10 | (주)케어젠 | 이소트레티노인-펩타이드 결합체를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 |
| KR102171141B1 (ko) * | 2018-05-28 | 2020-10-28 | 중앙대학교 산학협력단 | Lgi3 유래 펩타이드를 유효성분으로 포함하는 비만의 예방, 치료, 또는 개선용 조성물 |
| CN108676073B (zh) * | 2018-06-07 | 2021-10-26 | 华南理工大学 | 一种抗肥胖十肽llvvypwtqr及其应用 |
| CN109081862A (zh) * | 2018-06-07 | 2018-12-25 | 华南理工大学 | 一种抗肥胖四肽pqtr及其应用 |
| CN112010941B (zh) * | 2019-05-31 | 2022-08-16 | 华南理工大学 | 一种降血糖七肽 |
| CN113248628B (zh) * | 2021-07-13 | 2021-10-22 | 南京市妇幼保健院 | 一种乳源多肽衍生物及其在制备肥胖症防治药物、保健品和食品添加物中的应用 |
| KR20230046870A (ko) * | 2021-09-30 | 2023-04-06 | (주)케어젠 | 항비만 활성을 갖는 펩타이드 및 이의 용도 |
| KR20230138832A (ko) * | 2022-03-24 | 2023-10-05 | (주)케어젠 | 항당뇨 활성을 갖는 펩타이드 복합체 및 이의 용도 |
| KR20230148629A (ko) | 2022-04-18 | 2023-10-25 | (주)케어젠 | 항비만 및 항당뇨 활성을 갖는 펩타이드 및 이의 용도 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6693076B1 (en) * | 1989-06-05 | 2004-02-17 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
| US6723699B1 (en) * | 1989-06-05 | 2004-04-20 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
| US6310040B1 (en) | 1991-11-08 | 2001-10-30 | Cephalon, Inc. | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs |
| US5516891A (en) | 1992-06-16 | 1996-05-14 | Kinerton, Ltd. | Liquid phase synthesis of peptides and peptide derivatives |
| NZ255461A (en) * | 1992-08-20 | 1996-12-20 | Biotechnology & Biolog Science | Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity |
| WO1997031943A1 (en) * | 1996-03-01 | 1997-09-04 | Novo Nordisk A/S | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
| US6087334A (en) | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
| US20020132767A1 (en) | 2000-01-31 | 2002-09-19 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| IL150951A0 (en) * | 2000-02-18 | 2003-02-12 | Biovitrum Ab | Transgenic animal model for obesity expressing foxc2 |
| WO2001092523A2 (en) | 2000-05-30 | 2001-12-06 | Curagen Corporation | Human polynucleotides and polypeptides encoded thereby |
| PL362414A1 (en) * | 2001-02-19 | 2004-11-02 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
| CA2388287A1 (en) * | 2001-05-30 | 2002-11-30 | Terry E. Graham | Therapies for the prevention and treatment of diabetes and obesity |
| US7041646B2 (en) * | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
| NZ534699A (en) | 2002-01-18 | 2008-12-24 | Protemix Corp Ltd | Glycoisoforms of adiponectin and uses thereof |
| US20050143297A1 (en) | 2003-05-26 | 2005-06-30 | Jean-Pierre Rosat | Method for the administration of ligands, agonists of ligands of the TNF family with reduced toxicity |
| CN1980686A (zh) * | 2004-04-05 | 2007-06-13 | 安斯泰来制药有限公司 | 抗肥胖药 |
| US20070185025A1 (en) * | 2005-09-11 | 2007-08-09 | The Trustees Of Columbia University In The City Of New York | Filoviral immunosuppressive peptides and uses thereof |
| CA2636724A1 (en) | 2006-01-09 | 2007-08-02 | Children's Hospital Medical Center | Adiponectin for treatment of various disorders |
| EP2270039B1 (en) | 2006-03-06 | 2013-05-29 | Caregen Co., Ltd. | Peptides having activities of insulin like growth factor-1 and their uses |
| ES2529261T3 (es) * | 2006-06-09 | 2015-02-18 | Novartis Ag | Polipéptidos estabilizados del factor de crecimiento similares a insulina |
| CN101091765A (zh) * | 2007-06-08 | 2007-12-26 | 余仁生国际有限公司 | 药物组合物及其预防和治疗糖尿病的用途 |
| KR101050429B1 (ko) * | 2009-03-18 | 2011-07-19 | 연세대학교 산학협력단 | 캠펜을 유효성분으로 포함하는 비만, 이상지방혈증, 지방간또는 인슐린 저항성 증후군의 예방 또는 치료용 조성물 |
| EP2654774A4 (en) | 2010-12-22 | 2015-07-01 | Marcadia Biotech Inc | METHOD FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS WITH GIP AND GLP-1 RECEPTOR ACTIVE PUCIDIDES ON GLUCAGON BASIS |
| ES2538694T3 (es) * | 2011-04-01 | 2015-06-23 | F. Hoffmann-La Roche Ag | Variantes de la T7 ARN polimerasa con sustituciones de Cisteína-Serina |
| KR101363455B1 (ko) * | 2011-09-09 | 2014-02-21 | (주)케어젠 | 매트릭스 메탈로프로테아제 활성 억제 펩타이드 및 이의 용도 |
| KR20140027594A (ko) * | 2012-07-23 | 2014-03-07 | 씨지케이바이오 주식회사 | 항당뇨 및 항비만 활성을 갖는 약학 조성물 |
| ES2704280T3 (es) | 2012-09-21 | 2019-03-15 | Dow Global Technologies Llc | Método para tratar tejidos con un agente fijador de tinte |
| EP3395358B1 (en) * | 2012-09-26 | 2019-11-06 | Indiana University Research and Technology Corporation | Insulin analog dimers |
| KR101510742B1 (ko) | 2013-05-13 | 2015-04-10 | (주)케어젠 | 비만세포―특이적 아팝토시스-유도용 펩타이드 및 이의 용도 |
| DK3116526T3 (da) | 2014-03-13 | 2020-01-02 | Univ Grenoble Alpes | Farmakologiske sammensætninger, der omfatter april, til brug i behandlingen af multipel sclerose, autoimmun encephalitis, neuromyelitis optica, alzheimers-sygdom eller parkinsons-sygdom |
| KR101669140B1 (ko) | 2015-04-28 | 2016-10-26 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
-
2015
- 2015-04-28 KR KR1020150059648A patent/KR101669140B1/ko active IP Right Grant
- 2015-05-12 MY MYPI2021006165A patent/MY197888A/en unknown
- 2015-05-12 MX MX2017013847A patent/MX2017013847A/es unknown
- 2015-05-12 NZ NZ747392A patent/NZ747392A/en unknown
- 2015-05-12 MX MX2020012994A patent/MX2020012994A/es unknown
- 2015-05-12 ES ES19199355T patent/ES2893468T3/es active Active
- 2015-05-12 CA CA3074800A patent/CA3074800C/en active Active
- 2015-05-12 CA CA3074836A patent/CA3074836C/en active Active
- 2015-05-12 SG SG10201913490WA patent/SG10201913490WA/en unknown
- 2015-05-12 BR BR122020019077-9A patent/BR122020019077B1/pt active IP Right Grant
- 2015-05-12 ES ES19199390T patent/ES2895167T3/es active Active
- 2015-05-12 CN CN201910508327.2A patent/CN110105432B/zh active Active
- 2015-05-12 ES ES15890803T patent/ES2831329T3/es active Active
- 2015-05-12 MY MYPI2021006159A patent/MY197886A/en unknown
- 2015-05-12 EP EP19199388.0A patent/EP3613759B1/en active Active
- 2015-05-12 CN CN201910508329.1A patent/CN110172083B/zh active Active
- 2015-05-12 SG SG10201913487RA patent/SG10201913487RA/en unknown
- 2015-05-12 EP EP15890803.8A patent/EP3290434B1/en active Active
- 2015-05-12 US US15/569,322 patent/US10351597B2/en active Active
- 2015-05-12 CN CN201580004918.6A patent/CN106459152B/zh active Active
- 2015-05-12 MY MYPI2017704076A patent/MY192154A/en unknown
- 2015-05-12 JP JP2017556574A patent/JP6606192B2/ja active Active
- 2015-05-12 SG SG10201913489UA patent/SG10201913489UA/en unknown
- 2015-05-12 NZ NZ747390A patent/NZ747390A/en unknown
- 2015-05-12 BR BR122020019171-6A patent/BR122020019171B1/pt active IP Right Grant
- 2015-05-12 EP EP19199355.9A patent/EP3613758B1/en active Active
- 2015-05-12 ES ES19199388T patent/ES2894638T3/es active Active
- 2015-05-12 CA CA3074790A patent/CA3074790C/en active Active
- 2015-05-12 EA EA201792365A patent/EA037799B1/ru unknown
- 2015-05-12 NZ NZ747396A patent/NZ747396A/en unknown
- 2015-05-12 CA CA2984287A patent/CA2984287C/en active Active
- 2015-05-12 EP EP19199390.6A patent/EP3613760B1/en active Active
- 2015-05-12 AU AU2015393357A patent/AU2015393357B2/en active Active
- 2015-05-12 SG SG11201708847VA patent/SG11201708847VA/en unknown
- 2015-05-12 BR BR112017023199-9A patent/BR112017023199B1/pt active IP Right Grant
- 2015-05-12 MY MYPI2021006154A patent/MY197887A/en unknown
- 2015-05-12 NZ NZ737077A patent/NZ737077A/en unknown
- 2015-05-12 WO PCT/KR2015/004749 patent/WO2016175362A1/ko active Application Filing
- 2015-05-12 BR BR122020019095-7A patent/BR122020019095B1/pt active IP Right Grant
- 2015-05-12 MX MX2020012992A patent/MX2020012992A/es unknown
- 2015-05-12 MX MX2020012993A patent/MX2020012993A/es unknown
-
2017
- 2017-10-25 IL IL255263A patent/IL255263B/en unknown
- 2017-10-26 SA SA517390237A patent/SA517390237B1/ar unknown
- 2017-10-26 SA SA520420881A patent/SA520420881B1/ar unknown
- 2017-10-26 SA SA520420882A patent/SA520420882B1/ar unknown
- 2017-10-26 CL CL2017002718A patent/CL2017002718A1/es unknown
- 2017-10-26 SA SA520420880A patent/SA520420880B1/ar unknown
- 2017-10-27 PH PH12017501983A patent/PH12017501983A1/en unknown
- 2017-11-27 CO CONC2017/0011998A patent/CO2017011998A2/es unknown
- 2017-11-27 ZA ZA2017/08044A patent/ZA201708044B/en unknown
-
2018
- 2018-09-06 HK HK18111490.2A patent/HK1252251A1/zh unknown
-
2019
- 2019-03-20 US US16/359,675 patent/US10738081B2/en active Active
- 2019-03-20 US US16/359,613 patent/US11186611B2/en active Active
- 2019-03-20 US US16/359,645 patent/US10626145B2/en active Active
- 2019-05-24 AU AU2019203659A patent/AU2019203659B2/en active Active
- 2019-05-24 AU AU2019203657A patent/AU2019203657B2/en active Active
- 2019-05-24 AU AU2019203655A patent/AU2019203655B2/en active Active
- 2019-10-17 CL CL2019002960A patent/CL2019002960A1/es unknown
- 2019-10-17 CL CL2019002959A patent/CL2019002959A1/es unknown
- 2019-10-17 JP JP2019189873A patent/JP6813156B2/ja active Active
- 2019-10-17 JP JP2019189876A patent/JP6908085B2/ja active Active
- 2019-10-17 JP JP2019189870A patent/JP6813155B2/ja active Active
- 2019-10-17 CL CL2019002958A patent/CL2019002958A1/es unknown
-
2021
- 2021-04-21 IL IL282510A patent/IL282510B/en unknown
- 2021-04-21 IL IL282513A patent/IL282513B/en unknown
- 2021-04-21 IL IL282514A patent/IL282514B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017023199A2 (pt) | “peptídeo com atividade antiobesidade, antidiabetes e uso do mesmo” | |
| PH12018501969A1 (en) | Pharmaceutical composition comprising empagliflozin and uses thereof | |
| BR112017012327A8 (pt) | benzamidas substituídas por 1,3-tiazol-2-il. | |
| MY165124A (en) | Semifluorinated alkane compositions | |
| BR112014023379A8 (pt) | Microemulsões com base em ciclodextrina e usos dermatológicos das mesmas | |
| BR112015022514A2 (pt) | composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial | |
| BR112017000978A2 (pt) | mioinositol e probióticos e usos | |
| BR112016022854A2 (pt) | método para tratar, aliviar ou proteger (prevenir), diminuir o progresso ou reverter uma doença, método para tratar, aliviar ou proteger (prevenir) uma doença, uso, e, ácido nucleico ou gene | |
| BR112017007025A2 (pt) | sulfatos de colesterol oxigenados para terapia de distúrbios causados por pelo menos um de atividade de leptina atenuada e um distúrbio de armazenamento de lipídio | |
| BR112015021265A2 (pt) | métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes | |
| BR112015017903A2 (pt) | vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios | |
| BR112017008805A2 (pt) | tratamento de córnea usando laminina | |
| BR112017001803A2 (pt) | aril-hidrazidas contendo uma fração de 2-piridona como agentes antibacterianos seletivos | |
| BR112017001061A2 (pt) | combinação de vitamina d e zinco e seu uso | |
| BR112016023450A2 (pt) | uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce | |
| BR112014017160A8 (pt) | sistema de administração de fragrância duradoura | |
| BR112017009577A2 (pt) | análogos de pantotenamida | |
| BR112017001038A2 (pt) | vitamina b2 e seu uso | |
| CL2015001481A1 (es) | Uso de extracto bacopa monnieri | |
| BR112018010489A8 (pt) | tratamento para administração via oral, softgel, comprimido ou cápsula, método de redução dos efeitos psicoativos do thc em humanos, e solução ou tintura de lipossomos | |
| BR112017014823A2 (pt) | composto antimicrobiano, composição farmacêutica, uso de composto antimicrobiano e método de tratamento de pacientes | |
| BR112018001795A2 (pt) | preparação cosmética de redução do suor | |
| EA201892048A1 (ru) | Фармацевтическая композиция, содержащая эмпаглифлозин, и ее применения | |
| TH172399A (th) | การบำบัดโรคเบาหวานด้วยสูตรผสมอินซูลินที่ออกฤทธิ์นาน | |
| BR112018012621A2 (pt) | composições para higiene pessoal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/05/2015, OBSERVADAS AS CONDICOES LEGAIS |